Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.98 USD

100.98
592,706

+0.03 (0.03%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $100.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schein Expands SolutionsHub With CueSquared MobilePay

by Zacks Equity Research

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Zacks Equity Research

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Zacks Equity Research

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Zacks Equity Research

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Zacks Equity Research

Medtronic (MDT) Benefits from Strength Across Business Groups

by Zacks Equity Research

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Zacks Equity Research

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Zacks Equity Research

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Zacks Equity Research

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Zacks Equity Research

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Here's Why You Should Invest in DaVita (DVA) Stock For Now

by Zacks Equity Research

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) in Your Portfolio

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.

Zacks Equity Research

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Trina Mukherjee headshot

Outlook for Outpatient and Home Healthcare Industry Looks Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.

Zacks Equity Research

Moving Average Crossover Alert: Amedisys

by Zacks Equity Research

Amedisys, Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Sumit Singh headshot

Tap These 5 Stocks With Amazing Interest Coverage Ratio

by Sumit Singh

Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.

Zacks Equity Research

Is Amedisys (AMED) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Zacks.com featured highlights include: Marine Products, Amedisys, Universal Forest Products, NVR and AllianceBernstein

by Zacks Equity Research

Zacks.com featured highlights include: Marine Products, Amedisys, Universal Forest Products, NVR and AllianceBernstein

Zacks Equity Research

Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.

Zacks Equity Research

Company News for Aug 1, 2019

by Zacks Equity Research

Companies In The News Are: HABT, ZNGA, AMED, CHEF

Sanghamitra Saha headshot

Play DuPont Technique to Land on 5 Top-Ranked Stocks

by Sanghamitra Saha

Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.

Zacks Equity Research

Amedisys (AMED) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 24.74% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?